Compound class:
Synthetic organic
Comment: cis-JB253 is described in [1]. The structure is based upon that of the diabetes sulfonylurea drug glimepiride. This compound is formed from trans-JB253 upon photoisomerization using blue light. This isomerization process is reversible. The molecule is active in the cis-state, increasing insulin production from pancreatic B-cells in vitro. It is postulated that this type of photoswitchable compound could in the future, allow better control of blood glucose in diabetic patients [1].
Note that the PubChem CID we link to does not specify the cis-trans state of the compound. |
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
When sulfonylureas bind to SUR1 (the sulfonylurea receptor regulatory subunit), they act to block the Kir6.2 inward rectifier (the ion pore forming component of the KATP channel), leading to cell depolarization and opening of voltage-dependent Ca2+ channels [2]. This drives downstream processes that converge to increase insulin secretion [3]. |